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Abstract
Purpose: Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the
approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments.
KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR antibodies in colorectal cancer, and anti-
EGFR antibodies use was limited to KRAS wild type tumors. In order to ensure wide access to tumor molecular profiling, the
French National Cancer Institute (INCa) has set up a national network of 28 regional molecular genetics centers.
Concurrently, a nationwide external quality assessment for KRAS testing (MOKAECM) was granted to analyze reproducibility
and costs.
Methods: 96 cell-line DNAs and 24 DNA samples from paraffin embedded tumor tissues were sent to 40 French
laboratories. A total of 5448 KRAS results were collected and analyzed and a micro-costing study was performed on sites for
5 common methods by an independent team of health economists.
Results: This work provided a baseline picture of the accuracy and reliability of KRAS analysis in routine testing conditions at
a nationwide level. Inter-laboratory Kappa values were .0.8 for KRAS results despite differences detection methods and the
use of in-house technologies. Specificity was excellent with only one false positive in 1128 FFPE data, and sensitivity was
higher for targeted techniques as compared to Sanger sequencing based methods that were dependent upon local
expertise. Estimated reagent costs per patient ranged from J5.5 to J19.0.
Conclusion: The INCa has set-up a network of public laboratories dedicated to molecular oncology tests. Our results
showed almost perfect agreements in KRAS testing at a nationwide level despite different testing methods ensuring a cost-
effective equal access to personalized colorectal cancer treatment.
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Introduction
New therapeutic approaches such as anti-EGFR targeted
therapies and concurrent identification of molecular biomarkers
to identify sub-groups of potentially responsive tumors had created
a need for routine molecular characterization of cancers. In
colorectal cancer, the demonstration that patients with KRAS
mutated tumors did not benefit from anti-EGFR monoclonal
antibodies was established independently of the technology used to
identify KRASmutated tumors [1]. This result was rapidly followed
by a directive of the European Medicines Agency (EMEA) that
restricted the use of cetuximab (ErbituxH) and panitumumab
(VectibixH) to patients with KRAS wild-type metastatic colorectal
cancer [2].
With more than 940,000 new colorectal cancer cases worldwide
each year, the use of anti-EGFR targeted therapies are faced with
main issues, an economical one: who pays for the test or the drugs
and a medical one: who performs the test? The French public
health insurance system decided to provide targeted therapy for
colorectal cancer in line with the EMEA recommendation. In
parallel, the French government and the National Cancer Institute
(INCa) have set up a national network of 28 regional molecular
genetics centers to implement routine molecular testing for
colorectal cancer. More than one laboratory can be related to
one regional center.
Each laboratory developed KRAS testing according to its own
expertise and to the locally available instruments. The number of
tests increased from 1,100 in 2007 to 10,012 in 2008 and 17,246 in
2009. From then on, the number of tests was stable and covered
the expected incidence of metastatic colorectal cancer patients in
France. A founding of J2.5M was devoted to KRAS testing. This
organization seemed cost-effective considering global gain on drug
costs. It was necessary to prove that KRAS testing results were
reproducible between molecular laboratories. Each laboratory
using one or more genotyping method was evaluated by an
external quality control program, the multicenter program: KRAS
Oncogene Mutation detection in the treatment of Metastastic
Colorectal cancer by EGFR Antibodies (MOKAECM). The
MOKAECM project was set up as an external quality control and
laboratories were free to choose and develop their own method for
KRAS testing.
Previous comparative studies evaluated one technology [3],
[4,5]. Others compared different techniques with one tested
technology per site. In both cases the robustness of a technology
used with different levels of expertise cannot be evaluated [6] [7].
A national assessment of KRAS mutation testing linking actual
practices associated with cost evaluation has never been done up to
now.
The first objective of the MOKAECM project was to evaluate
at a nationwide level the performance of KRAS testing for clinical
purpose (sensitivity and reproducibility). The second was to
estimate and compare the costs associated to each technology.
As this study covers a national territory including all the INCa
labeled molecular laboratories, we may infer the national
performance for KRAS testing from the MOKAECM study.
Materials and Methods
Study Design
This study was designed to evaluate KRAS genotyping in 40
French laboratories related to one of the 28 molecular genetics
centers, using cell line and formalin-fixed paraffin-embedded
(FFPE) tumor samples. ADNs were centrally prepared to control
homogeneity and blindly sent to all participants for KRAS testing
using routine practice technologies. Results were loaded and
stored in a specific database and analyzed by a statistician (GC)
from the HEGP hospital Clinical Research Unit.
Cell Lines
ATCC Cells lines (H1573:p.G12A; H358:p.G12C;
A427:p.G12D; LS123:p.G12S; SW620:p.G12V; Lovo:p.G13D;
SW46:Wild Type) were specially purchased for the study and
KRAS G12R, was obtained by retroviral infection of 292FT cells
with a vector containing the KRAS c.34G.C substitution (JCP).
Colorectal Cancer Tissues Samples
Twenty-four tumors were characterized and selected from
patients undergoing surgical resection for colorectal cancer at the
Ambroise Pare´ Hospital, (Boulogne-Billancourt, France). The
Ethics committee of Ile de France II approved the study and
patients were informed and written consent was obtained
according to French law. The study was conducted in France.
Diagnosis of colorectal adenocarcinoma was assessed by a
pathologist (JFE) who selected the FFPE blocks for subsequent
molecular analysis. DNA extraction was done at the Ambroise Pare´
Hospital using the Qiamp DNA Mini Kit (Qiagen). The tumors
were characterized for KRAS by three different labs using three
different technologies. These laboratories were selected based on
their experience with KRAS testing and in house validation of the
method used. Selected samples showed no discrepancy.
Assessment of Cellularity
The evaluation of cellularity was performed at Hematoxylin,
eosin and safran (HES) slides at both ends of the FFPE block used
for DNA extraction. Slides were scanned on a Mirax Scan, (Zeiss,
Go¨ttingen, Germany). To validate the tumor cell content, the
scanned images were reviewed by seven independent pathologists
from different centers. When discrepancies were noticed, slides
were reviewed and consensus was found.
Methodology Used
Different in-house methods were developed: Sanger direct
sequencing (n = 15 laboratories), allelic discrimination probe
KRAS the MOKAECM French Country-Wide Experience
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systems [8,9] (n = 13), Snap Shot [10] (n = 7), pyrosequencing [11]
(n25), HRM followed by sequencing [12] (n = 5). One laboratory
used the TheraScreenH: K-RAS Mutation Kit commercial kit.
Five laboratories tested more than one method.
Thirty laboratories brought their entire protocol for KRAS
mutation detection, there was no practice homogeneity except for
laboratories using KRAS TaqManH probes (see Information S1).
Detailed procedures with primers positions are available on
request.
Statistical Approach and Data Analysis
Error rate was defined as the sum of false positives, false
negatives, non-contributive tests and wrong mutation calling. To
fit to the criteria used by the European EQA, all errors were at first
considered equally significant although the implication for patients
may differ. All samples were selected to have no amplification
default and each participant submitted a result that we considered
as being the final report sent to the oncologist. In a second step we
considered clinically relevant errors as being false positive and
negative results considering that in case of failure a new sample
would be requested although this will result in a further delay for
the patient.
Success rate was defined as the sum of true positives and true
negatives.
We assessed both reproducibility (inter- and intra-laboratory)
and diagnosis accuracy (sensitivity and specificity) of the different
techniques for KRAS genotyping. For each mutant cell line, there
were four different dilutions (5%, 20%, 50%, 100%) with three
replicates per dilution. All the data were taken into account.
For the six techniques, used by at least two laboratories, inter-
laboratory reproducibility was assessed using a generalization of
the Cohen Kappa statistics for measurement of agreement among
multiple rates [13]. In fact, each of the 96 samples was rated by m
laboratories – with m ranging from 2 to 15 according to the
technique- into one of the eight mutually exclusive categories. As
there were failures (inability for the technique to give a mutation
status), the calculation taking into account missing data. Confi-
dence intervals for the true generalized Kappa coefficient were
computed using the bootstrap resampling method, to take the
intra-cluster correlation into account [14].
For assessing intra-laboratory reproducibility for a given KRAS
genotyping technique, we computed a Kappa statistic for each
laboratory, as described above, based on the triplicate aliquots.
Then, we summarized the results by providing average Kappa
coefficients, with the range of Kappa coefficients across labora-
tories.
Diagnosis accuracy for the detection of each specific mutation
(categorical gold standard) was assessed for each technique and
each laboratory. Materials used in the two rounds can be
considered as gold standard materials (cell lines, validated tumor
DNAs). It was possible to assess a sensitivity and specificity for each
laboratory with cell line material and FFPE DNA samples. For
each technique, sensitivity and specificity for the detection of
mutation (binary gold standard) were computed by combining
data from all laboratories. A ratio estimator for the variance of
clustered binary data which takes intra-cluster correlations into
account was used for calculating 95%CI [15]. All analyses were
performed using the SAS software version 9.1.
Economical Assessment
Five technologies were compared: ‘‘Direct sequencing’’,
‘‘SNaPshot’’, ‘‘Pyrosequencing’’, ‘‘High Resolution Melting’’
(HRM), ‘‘TaqManH’’. Costs were estimated from the point of
view of the laboratory by microcosting and time-motion studies.
We estimated fixed and variable costs associated with each of the
five technologies: labor, consumables (i.e. reagent and others
consumables) and equipment and excluded overheads. Purchase
price was used for supplies and equipment with a 5-year linear
amortization and labor was valued using total payroll [16].
Cost Sensitivity Analysis
A sensitivity analysis was led to get a range of cost by moving
different parameters. The parameters were on prices (5% and
610%) and laboratory number of acts (Information S1).
Results
Analysis of Cell Line Results
Ninety-six cell-line DNA samples were sent to 40 French
laboratories, five laboratories used two different screening methods
leading to 4320 reported results. Since 6 laboratories could not
technically detect the p.G12R mutation (Information S1), the
p.G12R samples were not taken into account and 3780 results
were finally analyzed. Results were compared to the expected
Table 1. Diagnostic value comparison between methods cell line DNA analysis.
Labs (n) Samples (n) Analytical failures (n)
Success rate in true
negative (%) Success rate in true positive (%)
Dilutions
All 100% 50% 25% 5%
Direct sequencing 15 1260 4 (3%) 98.9 76 99 99 87.0 38
Taqman 8 672 11 (1.6%) 99.0 92.3 95.8 100 99.3 76.4
Snapshot 7 588 4 (7%) 98.8 89.7 95.2 100 93.7 73.8
Pyrosequencing 5 420 6 (14%) 95 96.6 100 100 100 89.7
HRM and sequencing 5 420 0 100 78.0 100 98.9 88.9 40.0
MASA 1 84 0 100 92.5 100 100 100 72.2
Scorpion 1 84 0 100 100 100 100 100 100
HRM+Taqman 1 84 0 100 100 100 100 100 33.3
PNAu based methods* 1+1 168 0 100 100 100 100 100 100
uPNA Peptide nucleic acid; *PNA was used with taqman probes or with allele specific PCR.
doi:10.1371/journal.pone.0068945.t001
KRAS the MOKAECM French Country-Wide Experience
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e68945
genotypes. The global error rate was 10.6% (399/3780), mainly
due to false negative results (89%, 357/399). Among those, 307
tests corresponded to a percentage of tumor cells of 5% while 50
involved samples with higher tumor cell ratios. The 42 remaining
errors were analytical failure (n = 25; 6%), false positive (n = 2;
0.5%) and wrong mutation (n= 15; 4%). Sequencing generated all
false positive results and demonstrated a false positive rate of 0.4%
(2/540). Wrong mutation callings were noted for sequencing
(0.8%, 11/1260) and snapshot (0.7%, 4/588).
For techniques performed by more than 2 laboratories,
sensitivity ranged from 76% to 96% and specificity from 95% to
100% (Table 1). Concerning 5% tumor samples, the lowest
sensitivity was found for sequencing and HRM with an overall
detection rate of approximately 40% as compared to 89.7% found
for pyrosequencing. A technical failure rate of 1.6% was observed
for Taqman probes due to a non-interpretation by 3 laboratories
of the triplicates corresponding to p.G12V (SW480 100%)
homozygous samples. Intra-laboratory and inter-laboratory re-
producibility were in almost perfect agreements (.0.8 for all
methods) and did not depend upon mutation type (Table 2).
Analysis of Tumor Sample Results
Concerning FFPE tissues, 1128 data were generated and
analyzed from 24 individual tumor samples (n = 47 methods, 40
different laboratories). The global error rate was 1.8% (20/1128)
with 1 false positive, 7 false negatives, 9 analytical failures and 3
wrong mutation callings. Individual tumor samples correct calls
ranged from 100% to 76.6%, indeed all laboratories correctly
genotyped 16/24 samples and one sample (a KRAS p.G12A
sample) generated mistakes by 11 laboratories. The 6 wild-type
samples were correctly genotype except in one case were a false
positive was reported by allelic discrimination qPCR based
method with a PNA blocker. Thirty-two out of 47 result sets
(laboratory/method) generated 0 error (68%), 13 made 1 (28%), 2
made 2 and one made 3 (Table 3). The three errors were 3
analytical failures using a pyrosequencing assay. This laboratory
also used direct sequencing with one false negative result. If
clinically relevant alterations (false positive and negative) and if
best results are considered when more than one method was
tested, 82.5% of the laboratories made no error and the success
rate ranged from 100 to 91,6. The remaining errors were 6 false
negative and one false positive in 7 laboratories. (Table S1).
Costs Per Item
Microcosting was assessed in site (n = 10 laboratories) by an
independent team of health economists. Costs are given per item
per test and total per test (Table 4). First labor costs ranged from
J3.7 (TaqMan) to J11.4 (SnaPshot) per test due to different
handling durations per sample from 7.2 (TaqMan) to 22.1 minutes
(SNaPshot). Small differences between laboratories using identical
technology were observed owing to slight variation in protocols and
to different equipments that influence efficiency and labor costs.
Moreover the number of samples run per batch also induces labor
cost variation. Second, equipment costs per test ranged from J1.0
to J9.7 depending on laboratories and technologies. Direct
sequencing was the most expensive technology with more than
J7 per test. Pyrosequencing, HRM and TaqMan were the least
expensive technologies with less than J2 per test. Sequencer,
Pyrosequencer and qPCR thermocycler generated 84% of equip-
ment costs. Machine costs per test varied according to duration of
runs, purchase prices and maximum number of samples per batch.
Third, consumables prizes per test ranged from J5.6 to J19.0.
Number of replicates, kind of reagents used, technical processes
and price negotiations explained most of the differences observed
from laboratories using the same technology. These differences
were particularly important for SnaPshot technique. One SnaP-
shot laboratory replicated experiments and used more expensive
reagents, leading to threefold higher consumable costs compared
to the second laboratory studied.
Total Costs
Total costs per test ranged from J10.6 to J34.8 (Table 4).
Moreover total cost for HRM needs to take into consideration
sequencing costs. About two thirds of samples were detected as
wild type KRAS genes by HRM and did not require sequencing.
We observed a rise of post ‘‘HRM’’ sequencing costs from J7 to
J13 compared to direct sequencing costs despite similar technol-
ogies. Therefore the global total cost per HRM test ranged from
J27.0 to J28.0.
Cost Sensitivity Analysis
Sensitivity analysis confirmed that TaqMan was less expensive
than other technologies (Figure 1). The estimated costs for
Table 2. Intra and Inter-laboratory reproducibility on cell line DNA.
Labs (n) Samples (n)
Intra-laboratory Kappa
score (CI 95%)
Inter-laboratory Kappa
score (CI 95%)
Direct sequencing 15 1260 0.93 [0.79–1] 0.86 [0.84–0.87]
Taqman 8 672 0.97 [0.92–1] 0.93 [0.93–0.94]
Snapshot 7 588 0.97 [0.97–1] 0.88 [0.86–0.89]
Pyrosequencing 5 420 0.98 [0.94–1] 0.95 [0.94–0.96]
HRM and sequencing 5 420 0.97 [0.94–1] 0.86 [0.85–0.87]
doi:10.1371/journal.pone.0068945.t002
Table 3. Global error rate for FFPE samples callings.
Labs (n) Samples (n) Errors
Direct sequencing 13 312 12(3.85%)
Taqman 9 216 0
Snapshot 6 144 1 (0.69%)
Pyrosequencing 7 168 3 (1.79%)
HRM and sequencing 6 144 2 (1.39%)
Others 6 144 2 (1.39%)
Total 47 1128 20 (1.74%)
doi:10.1371/journal.pone.0068945.t003
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TaqMan were optimal within the base case. Within the worse
conditions (five samples per batch and 10% prices markup)
TaqMan prices per test ranged from J15.7 to J20.1. Pyrose-
quencing costs per test were lower than 20.1J if at least 15
samples per batch were run.
Discussion
The use of anti-EGFR monoclonal antibodies is restricted to the
60 to 70% KRAS wild- type metastatic colorectal tumors, making
appropriate identification of KRAS mutations a key point for
Table 4. Costs per item and total costs per test per technique and laboratory.
Techniques Sequencing HRM SnaPshot Pyro-sequencing TaqMan
Laboratory # 1 2 1 2 1 2 1 2 1 2
Labor (J) 9.9 8.0 3.9 6.4 11.4 8.7 7.7 8.5 5.5 3.7
Equipment (J) 9.7 7.7 1.0 1.5 4.3 5.2 1.7 1.4 1.4 1.3
Consumables (J) 9.8 10.1 9.6 6.4 19.0 6.4 12.1 11.2 6.1 5.5
Total costs (J) 29.4 25.8 15.0 13.9 34.8 20.3 21.6 21.1 13.1 10.6
doi:10.1371/journal.pone.0068945.t004
Figure 1. Sensitivity analysis; Minimum, maximum and base case costs per test per technique and laboratory. Bleu diamonds rare base
case costs.
doi:10.1371/journal.pone.0068945.g001
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clinical practice [17,18]. Moreover limiting the use of EGFR
inhibitors to patients with wild-type KRAS may be a potential
solution for cost savings [19]. To ensure testing accessibility, the
INCa has granted 28 regional molecular genetics centers up to
2.5 MJ [20]. The aim of the countrywide quality control network
named MOKAECM, supported by the INCa, was to evaluate the
different in-house developed methods by molecular laboratories
for KRAS testing in routine conditions. Here, similar cell lines
(4296) and FFPE tumor samples ADNs (1152) were sent to the
different participants and 5448 KRAS genotyping results were
submitted and analyzed. Concerning the cell lines test, the error
rate was 10,6%, the detection cutoff ranged from 5 to 20% and
86% of false negative were related to the 5% dilution. 1152 FFPE
sample results were analyzed in this study, 68% of test sets
(method/laboratories) correctly identified the KRAS mutational
status in all FFPE samples. This result is comparable with the score
reported in the European KRAS EAQ scheme (70%) [21].
Recently, for KRAS mutation analysis in colorectal cancer,
arbitrary thresholds for correct KRAS mutation identification was
set at 97% [22]. Considering best results for laboratories testing
more than one method, the average success rate for FFPE samples
was 98.5 and ranged from 100 to 91.6% (Information S1). These
scores are in accordance with the results of a study ran in 10
laboratories in Netherlands [23]. Moreover, failure to attain an
overall testing event score of at least 80% was defined
unsatisfactory when testing a larger number of cases in the
‘Clinical Laboratory Improvement Act’ of 1988. Taking into
account results from the two testing sets 96% of French
laboratories had a satisfactory score over 80% that clearly shows
the quality of the KRAS testing in France despite the large panel
of methods. Moreover among in the 1152 tumors tested, only 20
errors were reported. This level of error is satisfying.
From a national perspective, on 1152 tumor tests in this study,
20 errors (0.017 CI95% [0.01–.027]) were reported with 11 of
them related to a single sample. Therefore the corrected error rate
was 0.7% CI95% [0.03%–0.13%] per test and per tumor. An
extrapolation suggests that in France, out of the 18,000 tumors
analyzed each year, 54 to 234 tumors could be misgenotyped.
Genotyping errors can result from different issues as the type of
fixative, the preservation procedure, the evaluation of the tumor-
cell content and finally the performances of the method used for
testing. Here, DNA extraction was centralized and tumor cell
content was validated by 7 independent pathologists therefore only
KRAS genotyping methods were compared. All selected samples
had a first validation of their KRAS status carried out by three
reference laboratories using three different methods. Many
different techniques, including commercially available kits, have
been developed and tested but the absence of a recognized
reference method makes the evaluation of new technologies a
difficult task.
Cell line testing may not reflect routine practices but was used as
a validation test in optimal conditions to compare the sensitivity
and specificity between the different technologies. For samples
with tumor cell line content over 20%, that can be considered
clinically relevant, analytical results showed almost perfect
agreements. For samples under 20%, results were more hetero-
geneous, especially for direct sequencing. In our experience, HRM
prescreening did not rescue low tumor content samples. The lower
sensitivity of sequencing methods as compared to others was not a
surprise [24,25,26], but our results also point out that performance
might depend on method optimization and level of expertise.
Indeed 7 laboratories using sequencing or HRM-sequencing had a
low error score (,10%) in the cell line series including 5% cell line
samples and no error in the tumor series. Sensitivity seems related
to a couple - methodology/laboratory-experience - rather than
strictly to a method, therefore validation and detection cutoff must
be assessed in each laboratory. When low sensitivity methods are
used for genotyping, macrodissection cutoff must be adequately
chosen and clear preanalytic recommendations must be given to
pathologists before DNA extraction. Regardless of the detection
method, mutation type could impact on sensitivity. The rate of
errors was around 3% with the p.G12V to more than 20% with
p.G12S and p.G12A. Allelic quantification of the 7 cell line DNAs
using pyrosequencing did not give any relevant explanation to the
reduced sensitivity observed for some mutations, and thermody-
namic consequences in the DNA melting behavior might, in part,
explain this observation. In the FFPE series the error rate was 20/
1128 (1.7%) versus 399/3780 (10.6%) in cell lines, for which errors
were mainly due to 5% tumor cell false negatives. The error rate
was 2.6% for cell lines in similar tumor content conditions (false
negative due to 5% samples excluded) suggesting that tissue
fixation was not an obstacle to KRAS testing. However, fixation
could slightly impact on failure levels: 0.8% (9/1128) on FFPE
samples versus 0.6% on cell line DNAs (25/3780). The use of
methods based on the amplification of small amplicons could be a
possibility to decrease the level of non-contributive results [27]. In
this study, methods based on allelic discrimination based on small
fragments amplification and real time PCR demonstrated no
failure against up to 4% for direct sequencing methods. Finally, in
the FFPE series, 14% of the errors were found in a single sample
for which tumor cell content was 50% after HES examination but
the quantification of mutated alleles by pyrosequencing suggested
that mutant cells could only represent 20% of all. This might in
part explain the discrepancies observed for this sample but also
suggests that genetic variations are not equally detected. One
FFPE false positive sample was identified by allele specific
amplification with a PNA blocker. It was not validated by another
laboratory using similar technology and was therefore considered a
false positive. Moreover the clinical value of mutated sub-clone
remains to be demonstrated [28,29,30,31,32].
Cost Estimates Limitations
This methodology of assessment of the cost was single handed
since the same independent team assessed all the technology
directly in the laboratories. Five technologies were studied by
microcosting in ten laboratories representing one third of all
French ‘‘platforms’’, which carried out 25% of all KRAS mutations
tests for metastatic colorectal patients in France in 2009. Although,
the level of evidence could be suboptimal, as it was based on 2
observations per technology, allelic discrimination using TaqMan
probes was about two or three times less expensive than any other
technology studied. Cost variation within one technology or
between technologies could be due to different procedures. Indeed
methods were not strictly identical, even in laboratories using
similar technology, and various degrees of optimization were
reported. An example was the management of testing procedure –
the number of positive and negative controls, the number of
replicates and the number of added steps to the procedure such as
gel migration of PCR products. These extra costs were valued.
Concerning cost equipment a saturation hypothesis was set at the
rate of eight hours per working day during five years. This could
not be the true situation for some laboratories and the estimated
costs underestimated true costs for laboratories. Moreover,
according to the saturation hypothesis of equipment, it is assumed
that the life expectancy of machines was similar for any kind of
machine, no information was available on the real life expectancy
of machines. Altogether microcosting data suggested that ‘‘in-
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house’’ technologies costs were much lower than commercial kits,
excluding equipment and labor costs.
Conclusion
The French population was 65,027,000 of inhabitants in 2011.
Twenty-eight regional molecular genetics centers covering all the
territories and coordinating 46 laboratories are now involved in
the analysis in 16,000 KRAS testing for metastatic colorectal
cancer each year. The whole network is nationally managed by the
INCa. This quality control program was the first countrywide
experience with 120 similar samples being analyzed by 40 different
laboratories. Our results demonstrate that, when clinically relevant
results are considered 82,5% of laboratories correctly identified the
KRAS mutational status in all FFPE samples. This work also
suggests that, while all methods are suitable for KRAS testing with
an average cost of J35 per test excluding the preanalytical steps,
differences exist in terms of sensibility and robustness. The choice
of the method is likely to depend on the equipment and technical
expertise available locally. This quality program provided a
baseline picture of KRAS testing in France. It showed that it is
possible at a reduced cost to set a nationwide program, it identified
errors in testing procedures for some laboratories underlining the
importance of optimization, in-house validation and quality
control processes using a large panel of mutations.
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